title: Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR.
abstract: OBJECTIVE
  To study the effect of the toxic secondary bile acid lithocholic acid (LCA) on the expression of fibroblast growth factor 19 (FGF19) in intestinal cells and to characterize the pregnane-X-receptor (PXR) response of the FGF19 promoter region.
  
  
  METHODS
  The intestinal cell line LS174T was stimulated with various concentrations of chenodeoxy-cholic acid and lithocholic acid for several time points. FGF19 mRNA levels were determined with quantitative realtime RT-PCR. FGF19 deletion promoter constructs were generated and the LCA response was analzyed in reporter assays. Co-transfections with PXR and RXR were carried out to study FGF19 regulation by these factors.
  
  
  RESULTS
  LCA and CDCA strongly up-regulate FGF19 mRNA expression in LS174T cells in a time and dose dependent manner. Using reporter gene assays with several deletion constructs we found that the LCA responsive element in the human FGF19 promoter maps to the proximal regulatory region containing two potential binding sites for PXR. Overexpression of PXR and its dimerization partner retinoid X receptor (RXR) and stimulation with LCA or the potent PXR ligand rifampicin leads to a significant induction of FGF19 promoter activity in intestinal cells.
  
  
  CONCLUSIONS
  LCA induced feedback inhibition of bile acid synthesis in the liver is likely to be regulated by PXR inducing intestinal FGF19 expression.
authors: Institute of Clinical Chemistry and Laboratory Medicine, University of Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg 93053, Germany.
authors: Wolfgang
authors: W
authors: Wistuba
authors: Carsten
authors: C
authors: Gnewuch
authors: Gerhard
authors: G
authors: Liebisch
authors: Gerd
authors: G
authors: Schmitz
authors: Thomas
authors: T
authors: Langmann
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D001483:Base Sequence; D045744:Cell Line, Tumor; D003902:Detergents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D025461:Feedback, Physiological / Q000502:physiology; D005346:Fibroblast Growth Factors / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D007414:Intestinal Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D008095:Lithocholic Acid / Q000494:pharmacology*; D008969:Molecular Sequence Data; D000077297:Pregnane X Receptor; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011987:Receptors, Steroid / Q000235:genetics / Q000378:metabolism*; D012293:Rifampin / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D015854:Up-Regulation / Q000187:drug effects
chemical_list: D003902:Detergents; D004791:Enzyme Inhibitors; C117476:FGF19 protein, human; D000077297:Pregnane X Receptor; D012333:RNA, Messenger; D011987:Receptors, Steroid; D008095:Lithocholic Acid; D005346:Fibroblast Growth Factors; D012293:Rifampin
references: Nat Clin Pract Gastroenterol Hepatol. 2006 Jul;3(7):358-9
references: 16819479
references: Mol Endocrinol. 2002 Jun;16(6):1269-79
references: 12040014
references: Am J Physiol Gastrointest Liver Physiol. 2007 Apr;292(4):G1114-22
references: 17170021
references: Science. 1999 May 21;284(5418):1362-5
references: 10334992
references: Mol Cell. 1999 May;3(5):543-53
references: 10360171
references: Mol Cell. 2000 Sep;6(3):507-15
references: 11030331
references: J Clin Invest. 2006 Aug;116(8):2280-2289
references: 16841097
references: Mol Cell. 2000 Sep;6(3):517-26
references: 11030332
references: Clin Chem. 2003 Feb;49(2):230-8
references: 12560344
references: Mol Pharmacol. 1999 Dec;56(6):1329-39
references: 10570062
references: J Clin Invest. 1998 Sep 1;102(5):1016-23
references: 9727070
references: Science. 1999 May 21;284(5418):1365-8
references: 10334993
references: J Biol Chem. 2002 Apr 26;277(17):14443-50
references: 11839742
references: J Hepatol. 2004 Mar;40(3):539-51
references: 15123373
references: Nat Med. 2006 Nov;12(11):1253-5
references: 17072310
references: Gastroenterology. 2004 Jul;127(1):26-40
references: 15236169
references: Endocr Rev. 2002 Oct;23(5):687-702
references: 12372848
references: Mol Endocrinol. 2005 Jul;19(7):1720-39
references: 15718292
references: Cell Metab. 2005 Oct;2(4):217-25
references: 16213224
references: Nucleic Acids Res. 2002 Jan 1;30(1):328-31
references: 11752328
references: J Biol Chem. 2002 Aug 30;277(35):31441-7
references: 12052824
references: Genes Dev. 2003 Jul 1;17 (13):1581-91
references: 12815072
references: J Biol Chem. 2005 Mar 4;280(9):7427-34
references: 15590640
references: Gastroenterology. 2006 Feb;130(2):341-8; quiz 592
references: 16472590
references: Proc Natl Acad Sci U S A. 2006 Mar 7;103(10 ):3920-5
references: 16473946
references: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13801-6
references: 12370413